The effect of the proportion of low-titer O whole blood for resuscitation in pediatric trauma patients on 6-, 12- and 24-hour survival.
Ethan M Petersen, Andrew D Fisher, Michael D April...
https://pubmed.ncbi.nlm.nih.gov/39898869/Actively Recruiting
Led by Philip Spinella · Updated on 2026-09-17
1000
Participants Needed
23
Research Sites
17 weeks
Total Duration
Researchers are evaluating treatments for children under 18 years old who experience life-threatening bleeding from traumatic injury. This trial aims to compare Low Titer Group O Whole Blood LTOWB with standard Component Therapy CT, as well as Tranexamic Acid TXA with a placebo, to determine their effects on reducing death within 24 hours after injury. The study also assesses safety outcomes like organ failure, infections, and blood clotting problems. Children enrolled in this randomized trial receive one of four combinations LTOWB with TXA, LTOWB with placebo, CT with TXA, or CT with placebo. LTOWB is blood from group O donors with low antibody levels, while CT includes red blood cells, plasma, and platelets given in a 111 ratio. TXA is given intravenously or intraosseously at a dose of 25 mgkg up to 2 grams to help prevent excessive bleeding. Up to 8 units of LTOWB may be given depending on clinical practice. During the study, participants are closely monitored for survival at various intervals including 6 hours, 24 hours, 72 hours, and 28 days. Researchers also track blood transfusion volumes within 24 hours and assess safety outcomes such as kidney injury, respiratory distress, heart problems, infections, and immune reactions. Blood and other samples are collected to study trauma-induced blood clotting disorders and how treatments affect these conditions. The trial is expected to continue through 2028, with participant follow-up lasting up to 28 days after treatment.
CONDITIONS
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
T
Thomas Byers
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Philip Spinella
Lead Sponsor
Biomedical Advanced Research and Development Authority
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | LTOWB + Tranexamic Acid | LTOWB + Placebo | Component Therapy + Tranexamic Acid | Component Therapy + Placebo |
|---|---|---|---|---|
| What it is | Randomized arm where children receive low titer group O whole blood plus tranexamic acid. | Randomized arm where children receive low titer group O whole blood plus placebo. | Randomized arm using balanced component therapy (1:1:1 red cells, plasma, platelets) plus tranexamic acid. | Randomized arm using balanced component therapy plus placebo. |
| Role in trial | Investigational whole blood strategy with antifibrinolytic adjunct. | Investigational whole blood strategy without antifibrinolytic. | Comparator arm using standard component resuscitation plus antifibrinolytic. | Comparator arm using component therapy without antifibrinolytic. |
| Primary use | Treatment of life‑threatening hemorrhage under massive transfusion protocol. | Treatment of life‑threatening hemorrhage under massive transfusion protocol. | Treatment of life‑threatening hemorrhage under massive transfusion protocol. | Treatment of life‑threatening hemorrhage under massive transfusion protocol. |
| How it is given or performed | Whole blood units administered along with IV or IO tranexamic acid dosing. | Whole blood units administered with placebo infusion. | Component therapy in 1:1:1 RBC‑plasma‑platelet ratio delivered with tranexamic acid. | Component therapy in 1:1:1 ratio delivered with placebo. |
| Evidence status | Observational data suggest LTOWB improves 72‑hour and 28‑day survival in pediatric massive transfusion. | Same observational survival data apply for LTOWB use regardless of TXA adjunct. | Component therapy remains standard but has lower survival compared to LTOWB in observational data. | Same observational inference applies when component therapy is administered without TXA. |
| Important risks | Safety profile of LTOWB in pediatrics shows no increased hemolysis or acute transfusion reactions in small cohorts. | Same safety observations apply when LTOWB is given without TXA. | Component therapy with TXA is widely used; TXA off‑label use in pediatric trauma has not shown clear safety concerns but lacks high‑quality data. | Component therapy alone considered standard of care with well‑understood safety profile. |
| Important limitations | Observational evidence is limited by small single‑center cohorts and potential confounding; randomized trial not yet completed. | Same observational evidence limitation applies. | Component therapy efficacy comparison limited by lack of randomized data and reliance on observational comparisons. | Placebo comparison limited by same trial design constraints. |
| Patient impact | Potential for improved short‑term survival and shorter ICU and ventilation time. | Same potential benefits apply without TXA adjunct. | Standard care with modest outcomes compared to LTOWB in observational findings. | Component therapy alone shows comparatively less favourable outcomes in observational data. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - Up to 24 hours
Participants receive assigned blood therapy (Low Titer Group O Whole Blood or Component Therapy) along with Tranexamic Acid or placebo.
Continuous monitoring during hospitalization
Duration - 28 days
Participants are monitored for survival and safety outcomes at 6 hours, 24 hours, 72 hours, and 28 days after treatment.
Several follow-up visits during this period
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Ethan M Petersen, Andrew D Fisher, Michael D April...
https://pubmed.ncbi.nlm.nih.gov/39898869/Philip Spinella
Lead Sponsor
Biomedical Advanced Research and Development Authority
Collaborating Sponsor